The median effective concentration of cyclopofol combined with different doses of esketamine for painless hysteroscopy

The median effective concentration of cyclopofo with different doses of esketamine during hysteroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077542

Enrollment

Unknown

Registered

2023-11-12

Start date

2023-11-12

Completion date

Unknown

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless hysteroscopy

Interventions

2:0.5mg/kgesketamine

3:0.25mg/kgesketamine

1:cyclopofol

Eligibility

Sex/Gender

Female

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: ?Age between 20 and 60 years old; ?ASA classification is between I-II; ?Operation time <1h; ?BMI index (body mass index) does not exceed 30; History or history of cervical dilation

Exclusion criteria

Exclusion criteria: ? Known history of allergic reactions to the planned medication; ? Long-term use of sedatives and analgesics; ? Severe ischemic heart disease, mental illness, chronic pain, pregnancy, seizures, increased intracranial pressure, and increased intraocular pressure; ? History of acute upper respiratory tract infection in the past 2 weeks; ? Participated in clinical trials of other drugs in the past 4 weeks or history of cervical dilation

Design outcomes

Primary

Measure	Time frame
EC50;	—

Secondary

Measure	Time frame
NRS;MAP;HR;	—

Countries

China

Contacts

Public ContactJianliang Sun

The First People's Hospital of Hangzhou, Zhejiang Province

jxmzsjl@163.com+86 139 5806 9878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026